- Home
- ANAB vs AOD Comparison
ANAB vs AOD Comparison
Compare ANAB & AOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- AOD
- Stock Information
- Founded
- ANAB 2005
- AOD 2006
- Country
- ANAB United States
- AOD United Kingdom
- Employees
- ANAB N/A
- AOD N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- AOD Investment Managers
- Sector
- ANAB Health Care
- AOD Finance
- Exchange
- ANAB Nasdaq
- AOD Nasdaq
- Market Cap
- ANAB 951.1M
- AOD 988.9M
- IPO Year
- ANAB 2017
- AOD N/A
- Fundamental
- Price
- ANAB $36.12
- AOD $9.54
- Analyst Decision
- ANAB Buy
- AOD
- Analyst Count
- ANAB 12
- AOD 0
- Target Price
- ANAB $59.30
- AOD N/A
- AVG Volume (30 Days)
- ANAB 365.9K
- AOD 423.5K
- Earning Date
- ANAB 10-31-2025
- AOD 01-01-0001
- Dividend Yield
- ANAB N/A
- AOD 12.95%
- EPS Growth
- ANAB N/A
- AOD 213.63
- EPS
- ANAB N/A
- AOD 1.93
- Revenue
- ANAB $123,164,000.00
- AOD $72,962,082.00
- Revenue This Year
- ANAB $24.36
- AOD N/A
- Revenue Next Year
- ANAB N/A
- AOD N/A
- P/E Ratio
- ANAB N/A
- AOD $4.44
- Revenue Growth
- ANAB 304.17
- AOD N/A
- 52 Week Low
- ANAB $12.21
- AOD $6.99
- 52 Week High
- ANAB $38.39
- AOD $9.14
- Technical
- Relative Strength Index (RSI)
- ANAB 72.97
- AOD 50.31
- Support Level
- ANAB $33.01
- AOD $9.59
- Resistance Level
- ANAB $35.58
- AOD $9.71
- Average True Range (ATR)
- ANAB 1.67
- AOD 0.12
- MACD
- ANAB -0.05
- AOD -0.02
- Stochastic Oscillator
- ANAB 68.61
- AOD 50.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.